This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Meeusen, E. N. T.
Right arrow Articles by Jungersen, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meeusen, E. N. T.
Right arrow Articles by Jungersen, G.

 Previous Article  |  Next Article 

Clinical Microbiology Reviews, July 2007, p. 489-510, Vol. 20, No. 3
0893-8512/07/$08.00+0     doi:10.1128/CMR.00005-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Current Status of Veterinary Vaccines

Els N. T. Meeusen,1* John Walker,2 Andrew Peters,3 Paul-Pierre Pastoret,4 and Gregers Jungersen5

Animal Biotechnology Research Laboratories, Department of Physiology, Monash University, Victoria 3800, Australia,1 VMRD Pfizer Australia, 52 Poplar Rd., Parkville, Victoria 3052, Australia,2 University of Edinburgh, Royal (Dick) School of Veterinary Studies, Easter Bush, Roslin, Midlothian EH25 9RG, United Kingdom,3 Publications Department, World Organisation for Animal Health, 12 rue de Prony, 75017 Paris, France,4 National Veterinary Institute, Technical University of Denmark, Bülowsvej 27, 1790 Copenhagen, Denmark5

The major goals of veterinary vaccines are to improve the health and welfare of companion animals, increase production of livestock in a cost-effective manner, and prevent animal-to-human transmission from both domestic animals and wildlife. These diverse aims have led to different approaches to the development of veterinary vaccines from crude but effective whole-pathogen preparations to molecularly defined subunit vaccines, genetically engineered organisms or chimeras, vectored antigen formulations, and naked DNA injections. The final successful outcome of vaccine research and development is the generation of a product that will be available in the marketplace or that will be used in the field to achieve desired outcomes. As detailed in this review, successful veterinary vaccines have been produced against viral, bacterial, protozoal, and multicellular pathogens, which in many ways have led the field in the application and adaptation of novel technologies. These veterinary vaccines have had, and continue to have, a major impact not only on animal health and production but also on human health through increasing safe food supplies and preventing animal-to-human transmission of infectious diseases. The continued interaction between animals and human researchers and health professionals will be of major importance for adapting new technologies, providing animal models of disease, and confronting new and emerging infectious diseases.


* Corresponding author. Mailing address: Department of Physiology, Building 13f, Monash University, Clayton, Victoria 3800, Australia. Phone: 61 3 99052513. Fax: 61 3 99052547. E-mail: els.meeusen{at}med.monash.edu.au


Clinical Microbiology Reviews, July 2007, p. 489-510, Vol. 20, No. 3
0893-8512/07/$08.00+0     doi:10.1128/CMR.00005-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:

  • Baszler, T. V., Shkap, V., Mwangi, W., Davies, C. J., Mathison, B. A., Mazuz, M., Resnikov, D., Fish, L., Leibovitch, B., Staska, L. M., Savitsky, I. (2008). Bovine Immune Response to Inoculation with Neospora caninum Surface Antigen SRS2 Lipopeptides Mimics Immune Response to Infection with Live Parasites. CVI 15: 659-667 [Abstract] [Full Text]